THREAD: Bring it down safely! ↘️💊
1/6 6⃣tweets about our new TI Therapeutics Letter 134: Finding the lowest effective dose for non-opioid #analgesics
👉🏾 Full Letter: ti.ubc.ca/letter134
#MedEd #medsafety #prescribing #BetterPrescribing
2/6 Consistent evidence that minority of pts get clinically meaningful pain relief from any dose of:
✅#Cyclobenzaprine (at best 1/4)
✅#Duloxetine (at best 1/6)
✅#Gabapentin / #Pregabalin (at best 1/6)
👉🏾ti.ubc.ca/letter134
#MedEd #ptsafety #BetterPrescribing #prescribing
3/6 Gabapentin, pregabalin, duloxetine:
A 2021 Canadian systematic review found NNT (numbers needed to treat) of 6-7 for "clinically meaningful benefit" (defined as ≥30% reduction in pain or pain & function)
👉🏾ti.ubc.ca/letter134
#MedEd #BetterPrescribing #deprescribing
4/6 Watch the Ceiling!👀
For duloxetine, #gabapentin, pregabalin:
@CochraneLibrary systematic reviews on treating chronic neuropathic pain or #fibromyalgia show exceeding “evidence-informed ceiling doses” doesn't↘️ mean pain scores
👉🏾ti.ubc.ca/letter134
#MedEd #ptsafety
5/6 Dose matters:
Cyclobenzaprine & duloxetine frequently cause anticholinergic effects including dry mouth, accelerated tooth decay, difficulty swallowing due to reduced salivation; delayed stomach emptying & constipation due to ↘️ gut motility
👉🏾ti.ubc.ca/letter134
6/6 Therapeutics Letter 134: Finding the lowest effective dose for non-opioid analgesics
See table below on evidence-informed dosing
👉🏾ti.ubc.ca/letter134
#MedEd #ptsafety #BetterPrescribing #prescribing
@threadreaderapp unroll, por favor : )
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.